Less Ads, More Data, More Tools Register for FREE

Pin to quick pickspolarean Regulatory News (POLX)

  • There is currently no data for POLX

Statement on Amphion Innovations

9 Aug 2019 16:14

RNS Number : 6193I
Polarean Imaging PLC
09 August 2019
 

Polarean Imaging Plc 

("Polarean" or the "Company")

 

Polarean notes statement from Amphion Innovations

 

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, notes the announcement made by its partner company, Amphion Innovations Plc ("Amphion") that 100,000 shares in Polarean have been sold for partial repayment of Amphion's loan facility which was originally announced on 5 June 2014 and most recently amended as announced on 1 April 2019.

 

Amphion now holds 18,272,523 ordinary shares in Polarean representing 15.97% of the issued share capital with voting rights. The full TR-1 disclosure is set out below.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

Enquiries: 

 

Polarean Imaging plc 

www.polarean.com / www.polarean-ir.com 

Richard Hullihen, Chief Executive Officer 

Via Walbrook PR 

Richard Morgan, Chairman 

 

 

 

SP Angel Corporate Finance LLP 

Tel: +44 (0)20 3470 0470  

David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance) 

 

 Vadim Alexandre / Rob Rees (Corporate Broking)

 

 

Walbrook PR 

Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com 

Anna Dunphy / Paul McManus 

Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 

 

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Polarean Imaging plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Amphion Innovations plc

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

August 8 2019

6. Date on which issuer notified (DD/MM/YYYY):

August 9 2019

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

15.97%

114,438,600

Position of previous notification (if

applicable)

16.05%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB008BVVT4H71

18,272,523

15.97%

SUBTOTAL 8. A

18,272,523

15.97%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London, UK

Date of completion

August 9 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLSSSFIUFUSEFA
Date   Source Headline
23rd Dec 20204:35 pmRNSPrice Monitoring Extension
23rd Dec 20207:00 amRNSFDA acceptance for filing of New Drug Application
4th Dec 20207:00 amRNSAppointment of Joint Corporate Broker
1st Dec 20204:41 pmRNSSecond Price Monitoring Extn
1st Dec 20204:36 pmRNSPrice Monitoring Extension
1st Dec 20202:06 pmRNSSecond Price Monitoring Extn
1st Dec 20202:01 pmRNSPrice Monitoring Extension
1st Dec 202011:05 amRNSSecond Price Monitoring Extn
1st Dec 202011:00 amRNSPrice Monitoring Extension
30th Oct 20207:00 amRNSTotal Voting Rights
23rd Oct 20204:41 pmRNSSecond Price Monitoring Extn
23rd Oct 20204:35 pmRNSPrice Monitoring Extension
23rd Oct 20202:05 pmRNSSecond Price Monitoring Extn
23rd Oct 20202:00 pmRNSPrice Monitoring Extension
20th Oct 20207:00 amRNSExercise of warrants
14th Oct 202011:00 amRNSPrice Monitoring Extension
12th Oct 20204:40 pmRNSSecond Price Monitoring Extn
12th Oct 20204:35 pmRNSPrice Monitoring Extension
12th Oct 20207:00 amRNSNew System Order
8th Oct 20205:05 pmRNSHolding(s) in Company
7th Oct 20207:00 amRNSNDA Submission
30th Sep 20207:00 amRNSHalf-year Report
18th Sep 20207:00 amRNSNew System Installation
30th Jul 20207:00 amRNSScientific presentations on hyperpolarized Xenon
13th Jul 20202:23 pmRNSResult of AGM
18th Jun 20207:00 amRNSFinal Results
1st Jun 20207:00 amRNSAppointment of Non-Executive Director
1st Jun 20207:00 amRNSExercise of Warrants
11th May 202011:05 amRNSSecond Price Monitoring Extn
11th May 202011:00 amRNSPrice Monitoring Extension
30th Apr 20206:30 pmRNSTotal Voting Rights
2nd Apr 20205:06 pmRNSHolding(s) in Company
2nd Apr 20202:12 pmRNSHolding(s) in Company
1st Apr 20203:32 pmRNSResult of General Meeting & Fundraise Completion
31st Mar 20207:00 amRNSTotal Voting Rights
25th Mar 20207:00 amRNSGeneral Meeting: Change of Venue
13th Mar 202012:51 pmRNSConditional Fundraise to raise £8.4 million
12th Mar 20204:41 pmRNSSecond Price Monitoring Extn
12th Mar 20204:36 pmRNSPrice Monitoring Extension
2nd Mar 20207:00 amRNSExercise of Warrants
3rd Feb 20207:00 amRNSDirectorate Change
29th Jan 20207:00 amRNSPositive pivotal Phase III Clinical Trials results
22nd Jan 20204:03 pmRNSDirector Dealing
13th Jan 20207:00 amRNSHolding(s) in Company
2nd Jan 20204:50 pmRNSDirector dealing
24th Dec 20197:00 amRNSNew System Delivery and Installation
12th Nov 20197:00 amRNSNew System Delivery and Installation
8th Nov 20197:00 amRNSGrant of options
7th Nov 20197:00 amRNSCompletion of patient enrolment & PDMR appointment
11th Oct 20194:17 pmRNSDirector dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.